Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma.

Translational lung cancer research·2026
Same author

Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Molecular Pathology of Lung Cancer.

Surgical pathology clinics·2026
Same author

Update on Pleural Epithelioid Mesothelioma: New Insights for Diagnosis and Patient Management.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.

The Journal of clinical investigation·2025
Same author

A Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2025

Related Experiment Video

Updated: Jun 27, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Pathologic Response Evaluation in Neoadjuvant-Treated Lung Cancer.

Sanja Dacic1

  • 1Department of Pathology Yale School of Medicine, 200 So Frontage Street, EP2-607, New Haven, CT 06510, USA.

Surgical Pathology Clinics
|May 1, 2024
PubMed
Summary

Major pathologic response (MPR) and pathologic complete response (pCR) are key endpoints in non-small cell lung cancer trials. Standardizing their assessment in resected tumors is crucial for reliable survival predictions.

Keywords:
Lung cancerNeoadjuvantPathologic responseResection

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

Related Experiment Videos

Last Updated: Jun 27, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

Area of Science:

  • Oncology
  • Pathology
  • Clinical Trials

Background:

  • Major pathologic response (MPR) and pathologic complete response (pCR) are emerging as critical early endpoints in non-small cell lung carcinoma (NSCLC) neoadjuvant clinical trials.
  • These metrics help predict patient survival outcomes in lung cancer treatment.
  • MPR is defined as ≤10% viable tumor, while pCR indicates no viable tumor remaining.

Purpose of the Study:

  • To highlight the growing importance of MPR and pCR in NSCLC neoadjuvant research.
  • To introduce the International Association for the Study of Lung Cancer (IASLC) recommendations for standardizing response assessment.
  • To emphasize the need for consistent evaluation of tumor response after neoadjuvant therapy.

Main Methods:

  • Review of current practices in NSCLC neoadjuvant clinical trials.
  • Discussion of the IASLC multidisciplinary recommendations for response assessment.
  • Focus on standardization of grossing and microscopic evaluation of resected lung carcinomas.

Main Results:

  • MPR and pCR are increasingly utilized as surrogate markers for survival in NSCLC.
  • The IASLC provided the first standardized guidelines for assessing MPR and pCR.
  • Standardization aims to improve the reliability and comparability of clinical trial results.

Conclusions:

  • Standardized pathologic assessment of MPR and pCR is essential for NSCLC neoadjuvant trials.
  • Consistent evaluation improves the interpretation of early endpoints and survival predictions.
  • The IASLC recommendations represent a significant step towards harmonizing response assessment in lung cancer research.